MING-WEI LEE2026-10-162026-10-162011-11-01Pure ID: 15340934Pure UUID: 178f5049-1b0c-4374-b389-9668d187de9e10.1177/0883911511423562https://www.scopus.com/pages/publications/81555220099https://scholars.csmu.edu.tw/handle/123456789/33099The purpose of this study was to develop a poly(galacturonic acid) (PGA)-based hydrogel using a short-chain hyaluronate (sHA) cross-linker for medical applications. PGA was grafted with adipic acid dihydrazide (ADH) to yield PGA-ADH, an amine-containing PGA derivative. This PGA-ADH formed a water-insoluble hydrogel by reacting with 1,1′-carbonyldiimidazole (CDI)-grafted sHA (sHA-CDI) in aqueous solution. The sHA-cross-linked PGA hydrogel has a water content of about 94%-97% and compressive modulus of 10.7-26.9 kPa. The in vitro data indicated that the sHA-cross-linked PGA hydrogel is degradable and noncytotoxic, thus suitable for biomedical applications. Animal implant studies showed that the sHA-cross-linked PGA hydrogel membrane exhibited antiadhesion potency, significantly higher than that found in untreated rats and has great potential for future clinical applications.13enPolygalacturonic acid hydrogel with short-chain hyaluronate cross-linker to prevent postoperative adhesionjournal article